Clinical trial
VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt
NCT00299325 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00299325 |
|---|---|
| Title | VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt |
| Official title | A Randomized, Double Blind, Two-arm Placebo Controlled, 12-Month Study of the Effects of Rimonabant 20mg Once Daily on the Amount and the Activity of Visceral Fat in Abdominally Obese Patients With Metabolic Syndrome. |
| Acronym | VICTORIA |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metabolic Syndrome |
| Intervention type | Drug, Other |
| Interventions | Rimonabant, Placebo (for Rimonabant), Mild hypocaloric diet |
| Enrollment | 254 |
| Start date | Feb 1, 2006 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Mar 6, 2006 |
| Last update posted | Jun 6, 2016 |
| Countries | Canada, Denmark, Finland, France, Italy, Spain, Sweden, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: